Literature DB >> 11052221

Electrophysiology of dopamine in normal and denervated striatal neurons.

P Calabresi1, D Centonze, G Bernardi.   

Abstract

Parkinson's disease (PD) symptoms originate from the loss of the dopaminergic control of neuronal activity in the striatum. Permanent loss of dopaminergic terminals in the striatum results in an abnormal activity of striatal neurons. The therapeutic treatment with exogenous dopamine, therefore, temporarily restores a balanced synaptic excitation of striatal neurons, counteracting pre- and postsynaptically the excessive glutamate release caused by the degeneration of nigrostriatal dopaminergic fibers. However, chronic treatment is associated with adverse effects that might reflect nonphysiological dopamine replacement. Basic studies on experimental animal models of PD are of crucial importance for the development of therapeutic agents able to provide relief to individuals with PD, without the adverse effects associated with currently available drugs.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 11052221     DOI: 10.1016/s1471-1931(00)00017-3

Source DB:  PubMed          Journal:  Trends Neurosci        ISSN: 0166-2236            Impact factor:   13.837


  30 in total

1.  Voltage-dependent membrane potential oscillations of rat striatal fast-spiking interneurons.

Authors:  Enrico Bracci; Diego Centonze; Giorgio Bernardi; Paolo Calabresi
Journal:  J Physiol       Date:  2003-03-28       Impact factor: 5.182

Review 2.  The lesion of the rat substantia nigra pars compacta dopaminergic neurons as a model for Parkinson's disease memory disabilities.

Authors:  Claudio Da Cunha; Miriam Elizabeth Mendes Angelucci; Newton S Canteras; Susan Wonnacott; Reinaldo N Takahashi
Journal:  Cell Mol Neurobiol       Date:  2002-06       Impact factor: 5.046

Review 3.  Synaptic plasticity in the mesolimbic dopamine system.

Authors:  Mark J Thomas; Robert C Malenka
Journal:  Philos Trans R Soc Lond B Biol Sci       Date:  2003-04-29       Impact factor: 6.237

4.  Corticostriatal functional interactions in Parkinson's disease: a rTMS/[11C]raclopride PET study.

Authors:  Antonio P Strafella; Ji Hyun Ko; Joshua Grant; Maria Fraraccio; Oury Monchi
Journal:  Eur J Neurosci       Date:  2005-12       Impact factor: 3.386

5.  Anatomical and electrophysiological changes in striatal TH interneurons after loss of the nigrostriatal dopaminergic pathway.

Authors:  Bengi Ünal; Fulva Shah; Janish Kothari; James M Tepper
Journal:  Brain Struct Funct       Date:  2013-10-31       Impact factor: 3.270

Review 6.  The hidden side of drug action: brain temperature changes induced by neuroactive drugs.

Authors:  Eugene A Kiyatkin
Journal:  Psychopharmacology (Berl)       Date:  2012-12-29       Impact factor: 4.530

7.  Experimental parkinsonism alters endocannabinoid degradation: implications for striatal glutamatergic transmission.

Authors:  Paolo Gubellini; Barbara Picconi; Monica Bari; Natalia Battista; Paolo Calabresi; Diego Centonze; Giorgio Bernardi; Alessandro Finazzi-Agrò; Mauro Maccarrone
Journal:  J Neurosci       Date:  2002-08-15       Impact factor: 6.167

8.  A53T-alpha-synuclein overexpression impairs dopamine signaling and striatal synaptic plasticity in old mice.

Authors:  Alexander Kurz; Kay L Double; Isabel Lastres-Becker; Alessandro Tozzi; Michela Tantucci; Vanessa Bockhart; Michael Bonin; Moisés García-Arencibia; Silke Nuber; Falk Schlaudraff; Birgit Liss; Javier Fernández-Ruiz; Manfred Gerlach; Ullrich Wüllner; Hartmut Lüddens; Paolo Calabresi; Georg Auburger; Suzana Gispert
Journal:  PLoS One       Date:  2010-07-07       Impact factor: 3.240

9.  Implanted reuptake-deficient or wild-type dopaminergic neurons improve ON L-dopa dyskinesias without OFF-dyskinesias in a rat model of Parkinson's disease.

Authors:  A Vinuela; P J Hallett; C Reske-Nielsen; M Patterson; T D Sotnikova; M G Caron; R R Gainetdinov; O Isacson
Journal:  Brain       Date:  2008-11-06       Impact factor: 13.501

10.  Homeostatic plasticity of striatal neurons intrinsic excitability following dopamine depletion.

Authors:  Karima Azdad; Marcelo Chàvez; Patrick Don Bischop; Pim Wetzelaer; Bart Marescau; Peter Paul De Deyn; David Gall; Serge N Schiffmann
Journal:  PLoS One       Date:  2009-09-04       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.